Last reviewed · How we verify
COLIRIOBCN070660
COLIRIOBCN070660 is a peptide-based therapeutic candidate developed by BCN Peptides, currently in phase 2 clinical development.
At a glance
| Generic name | COLIRIOBCN070660 |
|---|---|
| Also known as | Somatostatin eye drops |
| Sponsor | BCN Peptides |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Limited public information is available on the specific mechanism of action for COLIRIOBCN070660. As a BCN Peptides candidate in phase 2, it likely represents a peptide-based therapeutic approach, but the exact molecular target and mechanistic details require access to proprietary development data or clinical trial registries.
Approved indications
Common side effects
Key clinical trials
- Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COLIRIOBCN070660 CI brief — competitive landscape report
- COLIRIOBCN070660 updates RSS · CI watch RSS
- BCN Peptides portfolio CI